Effect of Ginger on liraglutide induced gastrointestinal side effects in patients with type 2 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251001067446N1

Enrollment

120

Registered

2025-11-14

Start date

2025-11-01

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 diabetes mellitus without complications

Interventions

Intervention 1: Intervention group: Participants in the intervention group will take 1 gram of standardized ginger capsules (500 mg per capsule) daily, on an empty stomach with a glass of water, with

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients diagnosed with type 2 diabetes who are scheduled to receive liraglutide therapy.

Exclusion criteria

Exclusion criteria: Contraindications to liraglutide therapy include a history of pancreatitis and thyroid cancer Patients with chronic conditions, such as type 1 diabetes, renal failure, cardiovascular disease, or hypertension, as well as those with a known allergy to ginger Patients who are currently using antiemetic medications Patients with severe gastrointestinal disorders Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
The primary outcomes include the severity of nausea, frequency of vomiting, constipation, severity of diarrhea, and changes in body weight. Timepoint: The intervention will be administered over a 4-week period, starting with the first day of gradual liraglutide injection. Ginger capsules will be taken on an empty stomach with a glass of water, with a second dose administered prior to dinner. Changes in outcome measures will be assessed on days 14 and 28 following treatment initiation. Method of measurement: Data on age, gender, and gastrointestinal symptom severity will be collected using a questionnaire at three time points: baseline (day 0), two weeks, and four weeks after the intervention begins. Patients’ body weight will also be measured and recorded at these time points. The presence of diarrhea or constipation will be documented, and nausea severity will be assessed using the Rhodes questionnaire.	—

Measure

Time frame

The primary outcomes include the severity of nausea, frequency of vomiting, constipation, severity of diarrhea, and changes in body weight. Timepoint: The intervention will be administered over a 4-week period, starting with the first day of gradual liraglutide injection. Ginger capsules will be taken on an empty stomach with a glass of water, with a second dose administered prior to dinner. Changes in outcome measures will be assessed on days 14 and 28 following treatment initiation. Method of measurement: Data on age, gender, and gastrointestinal symptom severity will be collected using a questionnaire at three time points: baseline (day 0), two weeks, and four weeks after the intervention begins. Patients’ body weight will also be measured and recorded at these time points. The presence of diarrhea or constipation will be documented, and nausea severity will be assessed using the Rhodes questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElaheh Mahmoudzadeh

Oroumia University of Medical Sciences

mahmoudzadeh.el@umsu.ac.ir+98 914 631 4786

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026